Correction to: Bone Marrow Transplantation https://doi.org/10.1038/s41409-022-01749-9, published online 07 July 2022
In the online version of article we state “Following informed consent, all three patients received fludarabine 100 mg/m2 on days -6 to -3, cyclophosphamide 60 mg/kg on days -3 and -2, and rabbit anti-thymocyte 16 globulin (r-ATG) 10 mg/kg on days -5 to -2”
It should be read as :
Following informed consent, all three patients received fludarabine 25 mg/m2 on days -6 to -2 (total dose 125 mg/m2), cyclophosphamide 60 mg/kg on days -3 and -2 (total dose 120 mg/kg) and rabbit anti-thymocyte globulin (r-ATG) 2.5 mg/kg on days -5 to -2 (total dose 10 mg/kg).
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rangarajan, H.G., Crowell, S.A., Towerman, A.S. et al. Correction to: CD34-selected stem cell boost as therapy for late graft rejection following allogeneic transplantation for sickle cell disease. Bone Marrow Transplant 57, 1855 (2022). https://doi.org/10.1038/s41409-022-01854-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-022-01854-9
